Rebate Reporting &
Transparency
Most rebate vendors give you one report. VativoRx delivers a structured reporting suite — monthly operational outputs, quarterly strategic reviews, and an advisory layer that goes beyond tracking what happened to informing what should happen next.
Schedule a Discovery CallWhy Reporting Breaks Down
When rebate reporting comes from multiple vendors in multiple formats, nobody has the full picture. Finance is reconciling one view, compliance is reviewing another, operations is working from a third.
Beyond the fragmentation problem, most reporting only tells you what was submitted and what was received. It doesn't tell you what you're missing — or what a different formulary decision could mean for next quarter's rebate picture.
A reporting suite should do more than document outcomes. It should give every stakeholder what they need to act — without requiring a custom request or a manual translation step between the data and the decision.
Structured Reporting Across All Stakeholders
VativoRx produces a defined reporting suite across every engagement — organized by cadence and audience so each stakeholder receives the output structured for their role.
Monthly outputs keep finance and operations current between quarters. Quarterly reviews give leadership and finance the context they need for planning and reconciliation. The advisory layer goes further — turning the reporting into a prompt for better decisions, not just a record of past ones.
The Six Report Types
Every report in the suite has a defined audience, a defined cadence, and a defined purpose. Nothing is produced on request — everything is structured into the program from the start.
How many claims were submitted this month? What was activity volume across our drug mix?
Which specific claims were submitted? What was the rebate eligibility status of each?
How did the quarter perform? What is the story across the full rebate cycle?
What should we expect to receive next quarter? How do we plan around rebate timing?
What was actually paid out? How does it reconcile against what was submitted and estimated?
Are there rebate-eligible alternatives to drugs currently outside our programs? Where might a formulary conversation be worth having?